Merck & Co., Inc. with ticker code (MRK) now have 26 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $122.25 and $93.27 suggesting an average Analsyt target price of $112.55. Now with the previous closing price of $107.98 this now indicates there is a potential upside of 4.2%. The 50 day moving average now sits at $103.78 and the 200 moving average now moves to $108.17. The total market capitalization for the company now stands at 275.63B. The current share price for the company is: $108.77 USD
The potential market cap would be $287,290,540,678 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 60.77, revenue per share of $23.38 and a 5.4% return on assets.
Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, including biological therapies, vaccines and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services for the prevention, treatment and control of disease in all major livestock and companion animal species.
